THALES
12.10.2020 14:32:06 CEST | Business Wire | Press release
For the 2020 edition of Les Assises de la Sécurité, Thales launches the newest edition of its CyberThreat Handbook, this year dedicated to cybercriminals. Thales’ experts unveil their analysis and conclusions when it comes to cybercrime, an extremely dangerous network with a large number of hackers groups. Interactions and permanent movements unite organised cybercrime and bring it to life. Without protection or proactive means, the attacks of cybercriminals will create each time more damage. To face their always-evolving technics, a better understanding of the threat is key; advanced tools and services such as Threat Intelligence are an asset to anticipate this threat as much as possible.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005432/en/
By interacting as a network of cybercrime groups, cybercriminals are able to function increasingly effectively: each group specialises in a particular area, and the different groups collaborate to benefit from each other’s expertise. It is this specialisation that makes cybercriminals more effective, allowing them to concentrate on a given type of attack, while drawing on know-how from within the network.
Various groups of the most technically adept cyber attackers, with highly sophisticated compromise strategies and substantial financial resources, head this organisation. These are the “Big Game Hunters”, whose tactics, techniques and procedures (TTPs) and technical infrastructure are similar to certain state-sponsored hacking groups. They attack specific targets, such as political institutions and major companies, using ransomware to demand large sums.
To achieve their objectives, cybercriminals use a combination of technical expertise and the panic that they sow in companies and institutions. Panic can have a devastating impact in terms of the consequences of an attack. It is vital not to give in to threats or blackmail. Cybercriminals’ targets are extremely diverse and opportunistic; any organization can suffer from it. Thales’ experts strongly recommend bearing in mind that anyone can be a target in order to be prepared and to adopt a clear and detailed cyber crisis strategy.
Surprisingly, 60% of these huge revenues come from illegal online markets, 30% from theft of intellectual property and trade secrets and only 0.07% from ransomware which however do the most damage. With revenues estimated up to $1.5 trillion a year 1 – meaning 1.5 times more income (as an annual average) than counterfeiting, and 2.8 times more than the illegal drugs trade – this network is a whole economic system that can now endanger any company or organization with severe consequences on the world’s economy.
For more information, download the press kit here and the report here .
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019. Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
FOR MORE INFORMATION
1 Research by the Cybersecurity firm Bromium, and Dr Mike McGuire, a researcher in criminology at the University of Surrey (UK)
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
